Filter by patients with: All

What is NSCLC Phase I PBF-509 AdenONCO Study?

Category: Others

false

NCT02403193 is a phase 1 dose escalation trial assessing the safety and feasibility of PBF-509 in patients with non-small cell lung cancer (NSCLC).

See patients taking NSCLC Phase I PBF-509 AdenONCO Study

Reported purpose & perceived effectiveness
Purpose Patients Evaluations Perceived Effectiveness
Participate in clinical trial 1 10
  • Major
  • Moderate
  • Slight
  • None
  • Can't tell
See 1 patient that have used NSCLC Phase I PBF-509 AdenONCO Study

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations Percentage
Severe 0
Moderate 1
Mild 7
None 2

Commonly reported side effects and conditions associated with NSCLC Phase I PBF-509 AdenONCO Study

Side effect Patients Percentage
Fatigue 1
Rash on torso 1
Adherence
Adherence Evaluations Percentage
Always 10
Usually 0
Sometimes 0
Never taken as prescribed 0
Burden
Burden Evaluations Percentage
Very hard to take 0
Somewhat hard to take 5
A little hard to take 5
Not at all hard to take 0
Cost per month
Cost per month Evaluations Percentage
$200+ 0
$100-199 0
$50-99 0
$25-49 0
< $25 10
Not specified 0
Last updated:
There are no evaluations for NSCLC Phase I PBF-509 AdenONCO Study.